Emerging drugs in endometriosis
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Endometriosis is a common, estrogen-dependent, gynaecological disease, defined as the presence of endometrial-like tissue outside the uterus. Although several medications are used for treatment of the disease, they are associated with high recurrence rates, considerable side effects and limited duration of application. Due to these limitations and to the impact of endometriosis on the quality of life of affected women, their environment and the society, there is a great need for new drugs able to abolish endometriosis and its symptoms. Studies in recent years investigating the (patho)physiological mechanisms involved in disease aetiology have fostered the development of novel therapeutic concepts for endometriosis, by targeting the hypothalamic-pituitary-gonadal axis, by selective modulation of estrogenic and progestogenic pathways, by inhibiting angiogenesis or by interfering with inflammatory and immunological factors. This article presents a brief summary of the currently available medications and an overview regarding the development of some of the most interesting and/or most promising novel drug candidates for endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“Furthermore, long-term use of COX-2 inhibitors has been associated with increased risk of cardiovascular side effects [135], which can be a serious limiting factor.”
BackgroundEstrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045 · cited 1×
“The first one, ERα, is thought to be responsible for mediating many of estrogen’s actions, such as its tropic effects on the uterus and feedback of the hypothalamic–pituitary–ovarian axis [111].”
BackgroundRegulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 7×
“Currently available drugs can improve endometriosis-associated pain, but are useless for endometriosis-associated subfertility [9] and are limited in terms of duration of drug application, side effects and disease recurrence after cessation of therapy.”
BackgroundMethodInfluentialSelf-citationThe PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345 · cited 1×
“PPARs have been shown to mediate anti-inflammatory processes [153-155].”
BackgroundAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 1×
“In addition, aromatase mRNA has been detected in the eutopic endometrial samples of women with moderate-to-severe endometriosis, although in much smaller quantities than in endometriotic implants [72].”
BackgroundVascular endothelial growth factor (VEGF) in endometriosis
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F., & Nisolle, M. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1686 · Cited by 531 · cited 1×
“Increased levels of proangiogenic factors have been demonstrated in endometriotic tissue and peritoneal fluid from women with endometriosis [118].”
BackgroundEndometriosis and pelvic pain: epidemiological evidence of the relationship and implications
Fauconnier, A., & Chapron, C. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi029 · Cited by 522 · cited 1×
“Endometriosis occurs in 13 – 33% of infertile women [8], whereas this figure varies in the range of 2 – 50% for asymptomatic women undergoing laparoscopy for indications other than pelvic pain or subfertility [11].”
BackgroundPrediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial
Bedaiwy, M. A. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.426 · Cited by 485 · cited 1×
“TNF-α concentrations are increased in the peritoneal fluid of women with endometriosis, and its levels correlate with the stage of the disease [137].”
BackgroundOlive, D. L., & Pritts, E. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450407 · Cited by 340
Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease?
Matarese, G., De Placido, G., Nikas, Y., & Alviggi, C. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00051-0 · Cited by 315
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells
Noble, L. S. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.600 · Cited by 301
The impact of endometriosis upon quality of life: a qualitative analysis
Jones, G., Jenkinson, C., & Kennedy, S. (2004) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/01674820400002279 · Cited by 291 · cited 1×
“As shown by a recent study, these effects include decreased performance at work and in the household, negative self image, anxiety, poor sleep, and so on [13].”
BackgroundVercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289 · cited 1×
“Furthermore, a 2-year study of women with endometriosis-associated dysmenorrhoea not responding to previous cyclic COC treatment found that continuous COC administration provided significant reduction in menstrual pain [52].”
BackgroundTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Progestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei290 · Cited by 179
Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1315 · Cited by 168
Igarashi, T. M., Bruner-Tran, K. L., Yeaman, G. R., Lessey, B. A., Edwards, D. P., Eisenberg, E., & Osteen, K. G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.113 · Cited by 163
Aromatase in endometriosis and uterine leiomyomata
Bulun, S. E., Imir, G., Utsunomiya, H., Thung, S., Gurates, B., Tamura, M., & Lin, Z. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.012 · Cited by 154 · cited 1×
“This may result in serum levels of estradiol, which are capable of causing endometrial hyperplasia or even endometrial carcinoma [69].”
BackgroundCosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Progestogens for endometriosis: forward to the past
Vercellini, P. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg030 · Cited by 147 · cited 1×
“COCs are commonly used as initial therapy for women with chronic pelvic pain as they are generally well tolerated, have a relatively better side-effect profile and can be applied longer than other substances [53,54].”
BackgroundMeresman, G. F., Augé, L., Barañao, R. I., Lombardi, E., Tesone, M., & Sueldo, C. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03099-6 · Cited by 130 · cited 1×
“The use of COCs results in anovulation, decreased gonadotropin levels, reduced menstrual flow, decidualisation of endometriotic lesions, downregulation of cell proliferation and enhanced apoptosis in the eutopic endometrium [49].”
BackgroundEvers, J. L. H. (1987) · Fertility and Sterility · doi:10.1016/s0015-0282(16)59062-1 · Cited by 118
Tamura, M., Deb, S., Sebastian, S., Okamura, K., & Bulun, S. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.09.076 · Cited by 107 · cited 1×
“In addition, estrogen can increase prostaglandin E (PGE)2 formation by stimulating the COX-2 enzyme in uterine endothelial cells in culture [70].”
BackgroundOkada, H. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.4.341 · Cited by 104 · cited 1×
“These data imply that dienogest could potentially suppress the growth of endometriotic implants [90].”
BackgroundBruner-Tran, K. L., Zhang, Z., Eisenberg, E., Winneker, R. C., & Osteen, K. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2024 · Cited by 65
Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005) · Journal of Investigative Surgery · doi:10.1080/08941930591004412 · Cited by 60
High-dose pilot study with the novel progestogen dienogestin patients with endometriosis
Schindler, A. E., Christensen, B., Henkel, A., Oettel, M., & Moore, C. (2006) · Gynecological Endocrinology · doi:10.1080/09513590500431482 · Cited by 53 · cited 1×
“In 16 subjects with adhesions, dienogest therapy also resulted in a significant 62% decrease in the mean adhesion scores [91].”
BackgroundKyama, C. M., T’Jampens, D., Mihalyi, A., Simsa, P., Debrock, S., Waelkens, E., Landuyt, B., Meuleman, C., Fulop, V., Mwenda, J. M., et al. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.12.024 · Cited by 46 · cited 1×
“With the possibilities provided by improved molecular technologies, it will hopefully become possible to identify biological features that are exclusively (or almost exclusively) present or absent in endometriosis, allowing specific targeting of ectopic lesions, and could open completely new horizons in the diagnosis…”
BackgroundSelf-citationMihalyi, A., Mutinda, K. C., Simsa, P., Debrock, S., Mwenda, J. M., & D’Hooghe, T. M. (2005) · Therapy · doi:10.2217/14750708.2.4.623 · Cited by 22 · cited 2×
“Substantial evidence indicates that immunological, inflammatory, genetic and environmental factors play major roles in this process [3,4].”
BackgroundSelf-citation
Cited by
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
Involvement of the nuclear factor-κB pathway in the pathogenesis of endometriosis
González-Ramos, R., Van Langendonckt, A., Defrère, S., Lousse, J.-C., Colette, S., Devoto, L., & Donnez, J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.01.013 · Cited by 179
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis
Olivares, C., Ricci, A., Bilotas, M., Barañao, R. I., & Meresman, G. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.063 · Cited by 65
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
Metadata
- Authors
- Mihalyi, A., Simsa, P., Mutinda, K. C., Meuleman, C., Mwenda, J. M., & D’Hooghe, T. M.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-08-29
- Volume
- 11
- Issue
- 3
- Pages
- 503-524
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2108818365
- Cited by
- 39
- References
- 34
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.